Longeveron LGVN 深 沪
等待开盘 04-02 09:30:00 美东时间
1.12
+0.080
+7.69%
华盛通- 最 高1.15
- 今 开1.04
- 成交量 150.68万股
- 最 低 1.025
- 昨 收 1.04
- 总市值 3279.49万
- 52周最高 1.83
- 市盈率 静 --
- 换手率 5.15%
- 52周最低 0.475
- 委 比 37.07%
- 总股本 2928.11万
- 历史最高 450.00
- 量 比 2.79
- 振 幅 12.02%
- 历史最低 0.475
- 每 手 1
- 风险率 0.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Longeveron Receives Extended Nasdaq Compliance Grace Period
Longeveron ( ($LGVN) ) has shared an update. On September 22, 2025, Longeveron ...
03-26 04:46
Longeveron Cancels Special Meeting, Reschedules Reverse Split Vote
Longeveron ( ($LGVN) ) has issued an update. On March 23, 2026, Longeveron Inc....
03-25 04:38
Longeveron Q4 EPS $(0.22) Beats $(0.32) Estimate, Sales $365.000K Beat $148.000K Estimate
Longeveron (NASDAQ:LGVN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.32) by 30.6 percent. This is a 18.52 percent increase over losses of $(0.27) per share from the
03-18 04:08
Longeveron Braces For Q4 Results Following Recent Funding Boost
Longeveron Inc. shares are trading higher Tuesday as investors pivot their focus toward the company's Q4 earnings report, due after the bell.
03-18 03:16
Earnings Scheduled For March 17, 2026
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is expected to ...
03-17 19:11
3 Penny Stocks to Watch Now, 3/11/26
Agape ATP ($ATPC), Longeveron ($LGVN), and MiNK Therapeutics ($INKT) are the 3&...
03-11 22:11
Longeveron shares are trading higher after the company announced a private placement of up to $30 million.
Longeveron shares are trading higher after the company announced a private plac...
03-11 00:09
Longeveron Commences $30M Private Placement
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it has entered into a
03-10 21:05
Longeveron Announces Private Placement of up to $30 Million
Longeveron Inc. (NASDAQ: LGVN) announced a $30 million private placement led by Coastlands Capital, with participation from Janus Henderson Investors and other healthcare-focused funds. The initial $15 million tranche is priced at-the-market under Nasdaq rules, with proceeds supporting the company's operations into Q4 2026, beyond the expected Phase 2b ELPIS II clinical trial data release in 3Q26. The company may receive an additional $15 million...
03-10 13:00
Watching Longeveron; Zacks Small-Cap Research Gives Stock $10.45 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_02262026_LGVN_Sorensen.pdf
02-27 00:05
